White & Case Advises Takeda on Agreement to Divest Select OTC and Non-Core Assets to STADA for US$660 Million
1 min read
Global law firm White & Case LLP has advised Takeda on the agreement to divest a portfolio of select products to STADA Arzneimittel AG for a total value of US$660 million.
The portfolio includes over-the-counter (OTC) and prescription pharmaceutical products exclusively in Russia, Georgia and a number of countries from within the Commonwealth of Independent States, which form part of Takeda's Growth & Emerging Markets Business Unit.
Takeda Pharmaceutical Company Limited is a global biopharmaceutical leader headquartered in Japan, primarily focused on five business areas: Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience.
STADA Arzneimittel AG is a publicly-listed company with headquarters in Germany. The company focuses on generics, including specialty pharmaceuticals and non-prescription consumer health products.
The White & Case team which advised on the transaction was led by partners Michael Immordino and Leonardo Graffi (both Milan and London) and included partners Philip Trillmich, Monica Holden, Dominic Ross, Nicholas Greenacre (all London), Arlene Arin Hahn (New York), James Hayden (New York), Axel Schulz (Brussels), Nikolay Feoktistov and Irina Dmitrieva (both Moscow), counsels Isaac Tendler (New York) and Ajita Shukla (Washington DC), and associates Andrea Pretti, Fabrizia Faggiano (both Milan), Chris Ewing, Kate Russell (both London), Kyle Oh (Singapore), Tommaso Poli (Brussels), Ksenia Tyunik, Alexander Karmalita and Roman Kudryavtsev (all Moscow) and lawyer Mariasole Maschio (Milan).
For more information please speak to your local media contact.